BACKGROUND: The Urticaria Patient Daily Diary (UPDD) is a validated patient-reported outcome that captures key measures of urticaria disease activity. OBJECTIVE: To update estimates of the minimal important difference (MID) for urticaria disease activity measures in the UPDD, including the weekly itch severity score, weekly number of hives score, weekly average size of largest hive score, and the composite measure of itch severity and number of hives over 7 days, or urticaria activity score 7 (UAS7). METHODS: A total of 975 subjects with chronic idiopathic urticaria from three randomized, double-blind, placebo-controlled studies completed the UPDD and other patient-reported outcome assessments (the Dermatology Life Quality Index, Medical Outcomes Study Sleep Scale, the Chronic Urticaria Quality-of-Life Questionnaire, the EuroQoL-5 Dimension Questionnaire) multiple times. MIDs were estimated through a combination of distribution- and anchor-based methods. RESULTS: MID estimates ranged from 4.5 to 5.0 for the weekly itch severity score, 5.0 to 5.5 for weekly hives count score, 9.5 to 10.5 for the UAS7, and 4.0 to 4.5 for the weekly size of the largest hive score. CONCLUSION: This analysis provided confirmation of the previous MID estimates for the urticaria disease activity measures in the UPDD.
RCT Entities:
BACKGROUND: The UrticariaPatient Daily Diary (UPDD) is a validated patient-reported outcome that captures key measures of urticaria disease activity. OBJECTIVE: To update estimates of the minimal important difference (MID) for urticaria disease activity measures in the UPDD, including the weekly itch severity score, weekly number of hives score, weekly average size of largest hive score, and the composite measure of itch severity and number of hives over 7 days, or urticaria activity score 7 (UAS7). METHODS: A total of 975 subjects with chronic idiopathic urticaria from three randomized, double-blind, placebo-controlled studies completed the UPDD and other patient-reported outcome assessments (the Dermatology Life Quality Index, Medical Outcomes Study Sleep Scale, the Chronic Urticaria Quality-of-Life Questionnaire, the EuroQoL-5 Dimension Questionnaire) multiple times. MIDs were estimated through a combination of distribution- and anchor-based methods. RESULTS: MID estimates ranged from 4.5 to 5.0 for the weekly itch severity score, 5.0 to 5.5 for weekly hives count score, 9.5 to 10.5 for the UAS7, and 4.0 to 4.5 for the weekly size of the largest hive score. CONCLUSION: This analysis provided confirmation of the previous MID estimates for the urticaria disease activity measures in the UPDD.
Authors: Mehran Alizadeh Aghdam; Edward F Knol; Mignon van den Elzen; Constance den Hartog Jager; Harmieke van Os-Medendorp; André C Knulst; Henny G Otten; Heike Röckmann Journal: Clin Exp Allergy Date: 2020-02-07 Impact factor: 5.018
Authors: Ana Giménez-Arnau; Marcus Maurer; Jonathan Bernstein; Petra Staubach; Nathalie Barbier; Eva Hua; Thomas Severin; Yolandi Joubert; Reinhold Janocha; Maria-Magdalena Balp Journal: Clin Transl Allergy Date: 2022-02 Impact factor: 5.871
Authors: Hing Yu Hung; Tianhe Song; Steven King Fan Loo; Kam Leung Chan; Jessica Yuet Ling Ching; Chi Him Sum; Louis Cho Wing Lo; Sarah Chon Pin Chia; Ray Tin Muk Ho; Pui Kuan Cheong; Tony Hon Chung Siu; Ka Chun Leung; Zhi-Xiu Lin Journal: Chin Med Date: 2022-07-22 Impact factor: 4.546
Authors: Hermenio Lima; Melinda Gooderham; Jan Dutz; Charles Lynde; Hugo Chapdelaine; Anne Ellis; Martin Gilbert; Vincent Ho; Kim Papp; Yves Poulin; Gordon Sussman Journal: Allergy Asthma Clin Immunol Date: 2017-08-24 Impact factor: 3.406
Authors: Ignacio Jauregui; Ana Gimenez-Arnau; Joan Bartra; Moises Labrador-Horrillo; Javier Ortiz de Frutos; Juan Francisco Silvestre; Joaquin Sastre; Manuel Velasco; Marta Ferrer; Cristina Ballesteros; Antonio Valero Journal: Health Qual Life Outcomes Date: 2019-01-31 Impact factor: 3.186